Loss of ARID1A drives a luminal-to-basal lineage modification in ER+ breast cancer, which decreases ER- dependent transcription and resistance to endocrine therapies such as fulvestrant by separating SWI/SNF from ER/GATA3/FOXA1-bound enhancers [28,29,31]. Here, ARID1A is linked to breast carcinoma.